Conformis Posts Clinical Study Data For Its Knee Implants

Conformis Inc (NASDAQ:CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant.
Data showed that implant survivorship was 98.5% with 8 revisions (representing 1.5% of the 540 implants reviewed) at a mean follow-up of 2.8 years.
89% of the patients reported being either satisfied or highly satisfied.
The researchers reviewed patient records and conducted patient report outcome surveys of 540 knees in 433 patients who underwent personalized total knee arthroplasty.
Related Link: Investors React To Conformis' Annual Sales Guidance Update.
Price Action: CFMS stock is up 1.55% at $1.31 during the premarket session on the last check Thursday.